⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PLRX News
Pliant Therapeutics, Inc. Common Stock
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
globenewswire.com
PLRX
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
globenewswire.com
PLRX
Form 8-K
sec.gov
PLRX
Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology
globenewswire.com
PLRX
Form 8-K
sec.gov
PLRX
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
globenewswire.com
PLRX
Form 8-K
sec.gov
PLRX
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
globenewswire.com
PLRX
Form 8-K
sec.gov
PLRX
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
globenewswire.com
PLRX